##gff-version 3
##sequence-region P04150 1 777
P04150	UniProtKB	Chain	1	777	.	.	.	ID=PRO_0000019937;Note=Glucocorticoid receptor	
P04150	UniProtKB	Domain	524	758	.	.	.	Note=NR LBD;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU01189	
P04150	UniProtKB	DNA binding	418	493	.	.	.	Note=Nuclear receptor;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00407	
P04150	UniProtKB	Zinc finger	421	441	.	.	.	Note=NR C4-type;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00407	
P04150	UniProtKB	Zinc finger	457	476	.	.	.	Note=NR C4-type;Ontology_term=ECO:0000255;evidence=ECO:0000255|PROSITE-ProRule:PRU00407	
P04150	UniProtKB	Region	1	420	.	.	.	Note=Modulating	
P04150	UniProtKB	Region	98	115	.	.	.	Note=Required for high transcriptional activity of isoform Alpha-C3;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23820903;Dbxref=PMID:23820903	
P04150	UniProtKB	Region	485	777	.	.	.	Note=Interaction with CLOCK	
P04150	UniProtKB	Region	487	523	.	.	.	Note=Hinge	
P04150	UniProtKB	Region	532	697	.	.	.	Note=Interaction with CRY1;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:22170608;Dbxref=PMID:22170608	
P04150	UniProtKB	Compositional bias	399	418	.	.	.	Note=Glu/Pro/Ser/Thr-rich (PEST region)	
P04150	UniProtKB	Modified residue	8	8	.	.	.	Note=Phosphothreonine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:23186163;Dbxref=PMID:23186163	
P04150	UniProtKB	Modified residue	23	23	.	.	.	Note=Omega-N-methylarginine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:P06537	
P04150	UniProtKB	Modified residue	45	45	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:23186163;Dbxref=PMID:23186163	
P04150	UniProtKB	Modified residue	113	113	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:P06537	
P04150	UniProtKB	Modified residue	134	134	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:18669648;Dbxref=PMID:18669648	
P04150	UniProtKB	Modified residue	141	141	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:P06537	
P04150	UniProtKB	Modified residue	203	203	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000244|PubMed:24275569,ECO:0000269|PubMed:12000743,ECO:0000269|PubMed:18483179,ECO:0000269|PubMed:25847991;Dbxref=PMID:24275569,PMID:12000743,PMID:18483179,PMID:25847991	
P04150	UniProtKB	Modified residue	211	211	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:12000743,ECO:0000269|PubMed:18483179,ECO:0000269|PubMed:25847991;Dbxref=PMID:12000743,PMID:18483179,PMID:25847991	
P04150	UniProtKB	Modified residue	226	226	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244,ECO:0000269;evidence=ECO:0000244|PubMed:18669648,ECO:0000269|PubMed:18483179;Dbxref=PMID:18669648,PMID:18483179	
P04150	UniProtKB	Modified residue	267	267	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244,ECO:0000244;evidence=ECO:0000244|PubMed:18669648,ECO:0000244|PubMed:23186163;Dbxref=PMID:18669648,PMID:23186163	
P04150	UniProtKB	Modified residue	404	404	.	.	.	Note=Phosphoserine%3B by GSK3-beta;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18838540;Dbxref=PMID:18838540	
P04150	UniProtKB	Modified residue	480	480	.	.	.	Note=N6-acetyllysine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19141540;Dbxref=PMID:19141540	
P04150	UniProtKB	Modified residue	492	492	.	.	.	Note=N6-acetyllysine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19141540;Dbxref=PMID:19141540	
P04150	UniProtKB	Modified residue	494	494	.	.	.	Note=N6-acetyllysine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19141540;Dbxref=PMID:19141540	
P04150	UniProtKB	Modified residue	495	495	.	.	.	Note=N6-acetyllysine;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19141540;Dbxref=PMID:19141540	
P04150	UniProtKB	Cross-link	258	258	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2);Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:28112733;Dbxref=PMID:28112733	
P04150	UniProtKB	Cross-link	277	277	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO)%3B alternate;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12144530;Dbxref=PMID:12144530	
P04150	UniProtKB	Cross-link	277	277	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)%3B alternate;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:28112733;Dbxref=PMID:28112733	
P04150	UniProtKB	Cross-link	293	293	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO)%3B alternate;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12144530;Dbxref=PMID:12144530	
P04150	UniProtKB	Cross-link	293	293	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO2)%3B alternate;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:25114211;Dbxref=PMID:25114211	
P04150	UniProtKB	Cross-link	419	419	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in ubiquitin);Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:P06537	
P04150	UniProtKB	Cross-link	703	703	.	.	.	Note=Glycyl lysine isopeptide (Lys-Gly) (interchain with G-Cter in SUMO);Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12144530;Dbxref=PMID:12144530	
P04150	UniProtKB	Alternative sequence	1	335	.	.	.	ID=VSP_058312;Note=In isoform Alpha-D3. Missing;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15866175;Dbxref=PMID:15866175	
P04150	UniProtKB	Alternative sequence	1	330	.	.	.	ID=VSP_058313;Note=In isoform Alpha-D2. Missing;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15866175;Dbxref=PMID:15866175	
P04150	UniProtKB	Alternative sequence	1	315	.	.	.	ID=VSP_058314;Note=In isoform Alpha-D1. Missing;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15866175;Dbxref=PMID:15866175	
P04150	UniProtKB	Alternative sequence	1	97	.	.	.	ID=VSP_058315;Note=In isoform Alpha-C3. Missing;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15866175;Dbxref=PMID:15866175	
P04150	UniProtKB	Alternative sequence	1	89	.	.	.	ID=VSP_058316;Note=In isoform Alpha-C2. Missing;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15866175;Dbxref=PMID:15866175	
P04150	UniProtKB	Alternative sequence	1	85	.	.	.	ID=VSP_058317;Note=In isoform Alpha-C1. Missing;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15866175;Dbxref=PMID:15866175	
P04150	UniProtKB	Alternative sequence	1	26	.	.	.	ID=VSP_018773;Note=In isoform Alpha-B and isoform Beta-B. Missing;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P04150	UniProtKB	Alternative sequence	313	338	.	.	.	ID=VSP_043908;Note=In isoform 10. Missing;Ontology_term=ECO:0000303;evidence=ECO:0000303|PubMed:17404046;Dbxref=PMID:17404046	
P04150	UniProtKB	Alternative sequence	451	451	.	.	.	ID=VSP_007363;Note=In isoform Alpha-2 and isoform Beta-2. G->GR;Ontology_term=ECO:0000303;evidence=ECO:0000303|Ref.6	
P04150	UniProtKB	Alternative sequence	491	674	.	.	.	ID=VSP_013340;Note=In isoform GR-A alpha and isoform GR-A beta. Missing;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P04150	UniProtKB	Alternative sequence	728	777	.	.	.	ID=VSP_003703;Note=In isoform Beta%2C isoform Beta-B%2C isoform Beta-2 and isoform GR-A beta. VVENLLNYCFQTFLDKTMSIEFPEMLAEIITNQIPKYSNGNIKKLLFHQK->NVMWLKPESTSHTLI;Ontology_term=ECO:0000303;evidence=ECO:0000303|PubMed:2867473;Dbxref=PMID:2867473	
P04150	UniProtKB	Natural variant	23	23	.	.	.	ID=VAR_014140;Note=Polymorphism%3B reduces transactivation activity%3B does not affect transrepression activity. R->K;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10391209,ECO:0000269|PubMed:10898924,ECO:0000269|PubMed:12351458,ECO:0000269|PubMed:15276593,ECO:0000269|PubMed:15292341,ECO:0000269|PubMed:16030164,ECO:0000269|PubMed:9150737,ECO:0000269|Ref.9;Dbxref=dbSNP:rs6190,PMID:10391209,PMID:10898924,PMID:12351458,PMID:15276593,PMID:15292341,PMID:16030164,PMID:9150737	
P04150	UniProtKB	Natural variant	29	29	.	.	.	ID=VAR_015628;Note=F->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10898924;Dbxref=dbSNP:rs148102613,PMID:10898924	
P04150	UniProtKB	Natural variant	65	65	.	.	.	ID=VAR_014622;Note=F->V;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10391209,ECO:0000269|Ref.9;Dbxref=dbSNP:rs6192,PMID:10391209	
P04150	UniProtKB	Natural variant	72	72	.	.	.	ID=VAR_075797;Note=Polymorphism%3B associated in cis with A-321 and S-766 in one individual%3B doubles transactivation potential. N->D;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:21701417;Dbxref=PMID:21701417	
P04150	UniProtKB	Natural variant	112	112	.	.	.	ID=VAR_015629;Note=L->F;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10898924;Dbxref=dbSNP:rs542110718,PMID:10898924	
P04150	UniProtKB	Natural variant	233	233	.	.	.	ID=VAR_015630;Note=D->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:10898924;Dbxref=dbSNP:rs1241576112,PMID:10898924	
P04150	UniProtKB	Natural variant	321	321	.	.	.	ID=VAR_075798;Note=Polymorphism%3B associated in cis with D-72 and S-766 in one individual%3B doubles transactivation potential. V->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:21701417;Dbxref=PMID:21701417	
P04150	UniProtKB	Natural variant	363	363	.	.	.	ID=VAR_004675;Note=Enhances transactivation activity%3B does not affect transrepression activity%3B may increase sensitivity to exogenously administered glucocorticoids%3B may contribute to central obesity in men and show lack of association with other risk factors for coronary heart disease and diabetes mellitus. N->S;Ontology_term=ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:10391209,ECO:0000269|PubMed:10898924,ECO:0000269|PubMed:11344238,ECO:0000269|PubMed:16030164,ECO:0000269|PubMed:8445027,ECO:0000269|PubMed:9150737;Dbxref=dbSNP:rs56149945,PMID:10391209,PMID:10898924,PMID:11344238,PMID:16030164,PMID:8445027,PMID:9150737	
P04150	UniProtKB	Natural variant	421	421	.	.	.	ID=VAR_015631;Note=C->Y;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:8358735;Dbxref=PMID:8358735	
P04150	UniProtKB	Natural variant	423	423	.	.	.	ID=VAR_075799;Note=In GCCR%3B unknown pathological significance%3B reduces transactivation activity%3B delays nuclear translocation%3B does not exert a dominant negative effect%3B impairs DNA binding. V->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23426617;Dbxref=PMID:23426617	
P04150	UniProtKB	Natural variant	477	477	.	.	.	ID=VAR_013472;Note=In GCCR. R->H;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11589680;Dbxref=dbSNP:rs104893913,PMID:11589680	
P04150	UniProtKB	Natural variant	477	477	.	.	.	ID=VAR_077143;Note=In GCCR%3B loss of DNA-binding and of transactivation activity%3B incomplete dexamethasone-induced translocation to the nucleus%3B no effect on dexamethasone-binding affinity compared with wild-type. R->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:27120390;Dbxref=PMID:27120390	
P04150	UniProtKB	Natural variant	478	478	.	.	.	ID=VAR_077144;Note=In GCCR%3B decreased DNA-binding and transactivation activity%3B incomplete dexamethasone-induced translocation to the nucleus%3B no effect on dexamethasone-binding affinity compared with wild-type. Y->C;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:27120390;Dbxref=PMID:27120390	
P04150	UniProtKB	Natural variant	556	556	.	.	.	ID=VAR_075800;Note=In GCCR%3B reduces transactivation activity%3B enhances transrepression activity%3B reduces affinity for ligand%3B delays nuclear translocation%3B does not exert a dominant negative effect%3B does not impair DNA binding. T->I;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:21362280,ECO:0000269|PubMed:26541474;Dbxref=PMID:21362280,PMID:26541474	
P04150	UniProtKB	Natural variant	559	559	.	.	.	ID=VAR_015632;Note=In GCCR%3B interferes with translocation to the nucleus and thereby strongly reduces transcription activation%3B is equally impaired in nuclear export%3B acts as dominant negative mutant. I->N;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11701741;Dbxref=dbSNP:rs104893909,PMID:11701741	
P04150	UniProtKB	Natural variant	571	571	.	.	.	ID=VAR_025014;Note=In pseudohermaphroditism%3B female with hypokalemia due to glucocorticoid resistance%3B 6-fold reduction in binding affinity compared with the wild-type receptor. V->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11932321;Dbxref=dbSNP:rs104893911,PMID:11932321	
P04150	UniProtKB	Natural variant	575	575	.	.	.	ID=VAR_075801;Note=In GCCR%3B unknown pathological significance%3B reduces transactivation activity%3B enhances transrepression activity%3B reduces affinity for ligand%3B delays nuclear translocation%3B does not exert a dominant negative effect%3B does not impair DNA binding. V->G;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:24483153;Dbxref=PMID:24483153	
P04150	UniProtKB	Natural variant	641	641	.	.	.	ID=VAR_004676;Note=In GCCR. D->V;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:1704018;Dbxref=dbSNP:rs104893908,PMID:1704018	
P04150	UniProtKB	Natural variant	672	672	.	.	.	ID=VAR_077145;Note=In GCCR%3B loss of dexamethasone-binding%2C dexamethasone-induced translocation to the nucleus and of transactivation activity. L->P;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:27120390;Dbxref=PMID:27120390	
P04150	UniProtKB	Natural variant	679	679	.	.	.	ID=VAR_013473;Note=In GCCR%3B has 50%25 binding affinity. G->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:11589680;Dbxref=dbSNP:rs104893914,PMID:11589680	
P04150	UniProtKB	Natural variant	714	714	.	.	.	ID=VAR_075802;Note=In GCCR%3B unknown pathological significance%3B reduces transactivation%3B reduces affinity for ligand%3B exerts a dominant negative effect%3B does not impair DNA binding. R->Q;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20335448;Dbxref=PMID:20335448	
P04150	UniProtKB	Natural variant	726	726	.	.	.	ID=VAR_075803;Note=In GCCR%3B unknown pathological significance%3B reduces transactivation and transrepression activity%3B reduces affinity for ligand%3B delays nuclear translocation%3B does not impair DNA binding. H->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:26031419;Dbxref=PMID:26031419	
P04150	UniProtKB	Natural variant	729	729	.	.	.	ID=VAR_004677;Note=In GCCR. V->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:7683692;Dbxref=dbSNP:rs1027058734,PMID:7683692	
P04150	UniProtKB	Natural variant	737	737	.	.	.	ID=VAR_071935;Note=In GCCR%3B reduces transactivation of the glucocorticoid-inducible tumor virus promoter%3B reduces affinity for ligand%3B delays its nuclear translocation%3B acts as dominant negative mutant. F->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:17635946;Dbxref=dbSNP:rs121909727,PMID:17635946	
P04150	UniProtKB	Natural variant	747	747	.	.	.	ID=VAR_015633;Note=In GCCR%3B alters interaction with NCOA2 and strongly reduces transcription activation%3B acts as dominant negative mutant. I->M;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12050230;Dbxref=dbSNP:rs104893910,PMID:12050230	
P04150	UniProtKB	Natural variant	753	753	.	.	.	ID=VAR_004678;Note=L->F;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:8316249,ECO:0000269|PubMed:8358735;Dbxref=dbSNP:rs121909726,PMID:8316249,PMID:8358735	
P04150	UniProtKB	Natural variant	766	766	.	.	.	ID=VAR_075804;Note=Polymorphism%3B associated in cis with D-72 and A-321 in one individual%3B doubles transactivation potential. N->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:21701417;Dbxref=PMID:21701417	
P04150	UniProtKB	Natural variant	773	773	.	.	.	ID=VAR_071936;Note=In GCCR%3B reduces transactivation of the glucocorticoid-inducible tumor virus promoter%3B reduces affinity for ligand%3B delays its nuclear translocation%3B acts as dominant negative mutant. L->P;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15769988;Dbxref=dbSNP:rs104893912,PMID:15769988	
P04150	UniProtKB	Mutagenesis	1	1	.	.	.	Note=Abolishes expression of A-type isoforms. M->T;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11435610,ECO:0000269|PubMed:15866175;Dbxref=PMID:11435610,PMID:15866175	
P04150	UniProtKB	Mutagenesis	27	27	.	.	.	Note=Abolishes expression of B-type isoforms. M->T;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:11435610,ECO:0000269|PubMed:15866175;Dbxref=PMID:11435610,PMID:15866175	
P04150	UniProtKB	Mutagenesis	86	86	.	.	.	Note=Abolishes expression of C-type isoforms%3B when associated with I-90 and I-98. M->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15866175;Dbxref=PMID:15866175	
P04150	UniProtKB	Mutagenesis	90	90	.	.	.	Note=Abolishes expression of C-type isoforms%3B when associated with I-86 and I-98. M->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15866175;Dbxref=PMID:15866175	
P04150	UniProtKB	Mutagenesis	98	98	.	.	.	Note=Abolishes expression of C-type isoforms%3B when associated with I-86 and I-90. M->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15866175;Dbxref=PMID:15866175	
P04150	UniProtKB	Mutagenesis	101	101	.	.	.	Note=Reduces transcription activation activity of isoform Alpha-C3 by half. D->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23820903;Dbxref=PMID:23820903	
P04150	UniProtKB	Mutagenesis	101	101	.	.	.	Note=Reduces transcription activation activity of isoform Alpha-C3 by half. Suppresses apoptosis-inducing activity of isoform Alpha-C3. Impairs recruitment of selected coregulators onto DNA binding sites. D->K;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23820903;Dbxref=PMID:23820903	
P04150	UniProtKB	Mutagenesis	106	107	.	.	.	Note=Reduces activity of isoform Alpha-C3 by half. QQ->LL;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23820903;Dbxref=PMID:23820903	
P04150	UniProtKB	Mutagenesis	113	114	.	.	.	Note=Does not affect the activity of isoform Alpha-C3. SS->AA;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:23820903;Dbxref=PMID:23820903	
P04150	UniProtKB	Mutagenesis	191	191	.	.	.	Note=Reduces transactivation by the ADA complex. F->D;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9154805;Dbxref=PMID:9154805	
P04150	UniProtKB	Mutagenesis	193	193	.	.	.	Note=Reduces transactivation by the ADA complex. I->D;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9154805;Dbxref=PMID:9154805	
P04150	UniProtKB	Mutagenesis	194	194	.	.	.	Note=Strongly reduces transactivation by the ADA complex%3B when associated with V-224 and F-225. L->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9154805;Dbxref=PMID:9154805	
P04150	UniProtKB	Mutagenesis	197	197	.	.	.	Note=Reduces transactivation by the ADA complex. L->E;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9154805;Dbxref=PMID:9154805	
P04150	UniProtKB	Mutagenesis	211	211	.	.	.	Note=Reduces expression of target genes IGFBP1 and IRF8. S->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18483179;Dbxref=PMID:18483179	
P04150	UniProtKB	Mutagenesis	213	213	.	.	.	Note=Strongly reduces transactivation by the ADA complex. W->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9154805;Dbxref=PMID:9154805	
P04150	UniProtKB	Mutagenesis	224	224	.	.	.	Note=Strongly reduces transactivation by the ADA complex%3B when associated with A-194 and F-225. L->V;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9154805;Dbxref=PMID:9154805	
P04150	UniProtKB	Mutagenesis	225	225	.	.	.	Note=Strongly reduces transactivation by the ADA complex%3B when associated with A-194 and V-224. L->F;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9154805;Dbxref=PMID:9154805	
P04150	UniProtKB	Mutagenesis	226	226	.	.	.	Note=Abolishes phosphorylation and enhances transcriptional activation. S->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18483179;Dbxref=PMID:18483179	
P04150	UniProtKB	Mutagenesis	235	235	.	.	.	Note=Strongly reduces transactivation by the ADA complex%3B when associated with V-236. F->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9154805;Dbxref=PMID:9154805	
P04150	UniProtKB	Mutagenesis	236	236	.	.	.	Note=Strongly reduces transactivation by the ADA complex%3B when associated with L-235. L->V;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:9154805;Dbxref=PMID:9154805	
P04150	UniProtKB	Mutagenesis	277	277	.	.	.	Note=Strongly reduces sumoylation. Almost complete loss of sumoylation%3B when associated with R-293. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12144530;Dbxref=PMID:12144530	
P04150	UniProtKB	Mutagenesis	293	293	.	.	.	Note=Strongly reduces sumoylation. Almost complete loss of sumoylation%3B when associated with R-277. K->R;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12144530;Dbxref=PMID:12144530	
P04150	UniProtKB	Mutagenesis	316	316	.	.	.	Note=Abolishes expression of D-type isoforms%3B when associated with I-331 and I-336. M->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15866175;Dbxref=PMID:15866175	
P04150	UniProtKB	Mutagenesis	331	331	.	.	.	Note=Abolishes expression of D-type isoforms%3B when associated with I-316 and I-336. M->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15866175;Dbxref=PMID:15866175	
P04150	UniProtKB	Mutagenesis	336	336	.	.	.	Note=Abolishes expression of D-type isoforms%3B when associated with I-316 and I-331. M->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:15866175;Dbxref=PMID:15866175	
P04150	UniProtKB	Mutagenesis	404	404	.	.	.	Note=Abolishes phosphorylation. Does not affect translocation to the nucleus following ligand stimulation. Increases protein half-life and transcriptional repressor activity. Alters repertoire of regulated genes. Increases cell death. S->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18838540;Dbxref=PMID:18838540	
P04150	UniProtKB	Mutagenesis	404	404	.	.	.	Note=Does not affect translocation to the nucleus following ligand stimulation. S->D;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:18838540;Dbxref=PMID:18838540	
P04150	UniProtKB	Mutagenesis	480	480	.	.	.	Note=Decrease in acetylation and in repression of its transcriptional activity by CLOCK-ARNTL/BMAL1 heterodimer. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-ARNTL/BMAL1 heterodimer%3B when associated with A-492%3B A-494 and A-495. K->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19141540;Dbxref=PMID:19141540	
P04150	UniProtKB	Mutagenesis	492	492	.	.	.	Note=Decrease in acetylation and in repression of its transcriptional activity by CLOCK-ARNTL/BMAL1 heterodimer. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-ARNTL/BMAL1 heterodimer%3B when associated with A-480%3B A-494 and A-495. K->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19141540;Dbxref=PMID:19141540	
P04150	UniProtKB	Mutagenesis	494	494	.	.	.	Note=Decrease in acetylation and in repression of its transcriptional activity by CLOCK-ARNTL/BMAL1 heterodimer%3B when associated with A-495. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-ARNTL/BMAL1 heterodimer%3B when associated with A-480%3B A-492 and A-495. K->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19141540;Dbxref=PMID:19141540	
P04150	UniProtKB	Mutagenesis	495	495	.	.	.	Note=Decrease in acetylation and in repression of its transcriptional activity by CLOCK-ARNTL/BMAL1 heterodimer%3B when associated with A-494. Complete loss in acetylation and in repression of its transcriptional activity by CLOCK-ARNTL/BMAL1 heterodimer%3B when associated with A-480%3B A-492 and A-494. K->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:19141540;Dbxref=PMID:19141540	
P04150	UniProtKB	Mutagenesis	585	585	.	.	.	Note=Reduces activation mediated by ligand binding domain%3B when associated with A-590. R->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12151000;Dbxref=PMID:12151000	
P04150	UniProtKB	Mutagenesis	590	590	.	.	.	Note=Reduces activation mediated by ligand binding domain%3B when associated with A-585. D->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12151000;Dbxref=PMID:12151000	
P04150	UniProtKB	Mutagenesis	602	602	.	.	.	Note=Increases solubility. No effect on transactivation by dexamethasone. F->S;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12151000;Dbxref=PMID:12151000	
P04150	UniProtKB	Mutagenesis	625	625	.	.	.	Note=Decreases transactivation by dexamethasone by 95%25. P->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12151000;Dbxref=PMID:12151000	
P04150	UniProtKB	Mutagenesis	628	628	.	.	.	Note=Decreases dimerization and transactivation by dexamethasone%3B when associated with S-602. I->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:12151000;Dbxref=PMID:12151000	
P04150	UniProtKB	Mutagenesis	703	703	.	.	.	Note=Slightly reduces sumoylation. Inhibits the stimulatory effect of RWDD3 on its transcriptional activity. K->R;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:12144530,ECO:0000269|PubMed:23508108;Dbxref=PMID:12144530,PMID:23508108	
P04150	UniProtKB	Sequence conflict	399	399	.	.	.	Note=R->G;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P04150	UniProtKB	Sequence conflict	754	754	.	.	.	Note=A->T;Ontology_term=ECO:0000305;evidence=ECO:0000305	
P04150	UniProtKB	Turn	422	424	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5E69	
P04150	UniProtKB	Beta strand	430	432	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5E69	
P04150	UniProtKB	Beta strand	435	437	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5E69	
P04150	UniProtKB	Helix	439	450	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5E69	
P04150	UniProtKB	Beta strand	458	461	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5E69	
P04150	UniProtKB	Turn	467	472	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5E69	
P04150	UniProtKB	Helix	474	484	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5E69	
P04150	UniProtKB	Helix	488	497	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:6CFN	
P04150	UniProtKB	Turn	525	527	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:1M2Z	
P04150	UniProtKB	Helix	532	538	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4UDD	
P04150	UniProtKB	Beta strand	550	552	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:3K22	
P04150	UniProtKB	Helix	556	579	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4UDD	
P04150	UniProtKB	Helix	584	586	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4UDD	
P04150	UniProtKB	Helix	589	615	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4UDD	
P04150	UniProtKB	Beta strand	617	619	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4P6W	
P04150	UniProtKB	Beta strand	621	624	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4UDD	
P04150	UniProtKB	Beta strand	627	629	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4UDD	
P04150	UniProtKB	Helix	631	634	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4UDD	
P04150	UniProtKB	Helix	639	655	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4UDD	
P04150	UniProtKB	Helix	660	671	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4UDD	
P04150	UniProtKB	Beta strand	673	675	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4UDD	
P04150	UniProtKB	Helix	683	702	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4UDD	
P04150	UniProtKB	Beta strand	704	706	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4P6W	
P04150	UniProtKB	Helix	708	741	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4UDD	
P04150	UniProtKB	Helix	743	745	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4UDD	
P04150	UniProtKB	Helix	751	765	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:4UDD	
P04150	UniProtKB	Helix	766	768	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:6DXK	
P04150	UniProtKB	Beta strand	769	771	.	.	.	Ontology_term=ECO:0000244;evidence=ECO:0000244|PDB:5UC3	
